This conclusion stems from research on ovarian cancer cells engineered to express a gene for vasohibin-1 (VASH1) that is normally expressed by endothelial cells in response to angiogenic stimuli and inhibits these cells’ motility autocrinally in a negative feedback mechanism [168]. The gene discussed is VASH1; the disease is ovarian cancer.